Subscribe
Share
Share
Embed
Truth Seekers: Where Data Meets Reality
Tired of sensational headlines and conflicting health advice? Join Alex Barrett and Bill Morrison as they cut through the noise to uncover what scientific research actually says about the claims flooding your social media feed.
Each week, Alex and Bill tackle a different health, nutrition, or wellness claim that everyone's talking about. From "blue light ruins your sleep" to "seed oils are toxic," they dig into the actual studies, examine the methodologies, and translate the data into plain English.
No agenda. No sponsors to please. No credentials to fake. Just two people committed to finding out what's really true by going straight to the source—the research itself.
Perfect for anyone who's skeptical of influencer health advice but doesn't have time to read every scientific study themselves. New episodes drop regularly, delivering clarity in a world full of clickbait.
Question everything. Verify with data. Find the truth.
Disclaimer: Truth Seekers provides educational content based on published research. Nothing in this podcast should be considered medical, financial, or professional advice. Always consult qualified professionals for decisions affecting your health and wellbeing.
---
**The Mystery Mechanism That Nobody Actually Found**
Alex: Right, so Wegovy and Ozempic—the weight loss drugs everyone's talking about—apparently protect your heart through some mysterious mechanism that has absolutely nothing to do with weight loss. That's the headline that's been everywhere since October.
Bill: Okay.
Alex: And it sounds brilliant, doesn't it? Like they've discovered this hidden superpower in the drug.
Bill: Well, hang on. It's based on a massive study—over seventeen thousand patients in The Lancet, four years of follow-up. They found that only about a third of the heart benefits could be explained by weight loss. Two-thirds unexplained.
Alex: Right, "Heart Benefits Extend Beyond Weight Loss," the British Heart Foundation saying patients got benefits "regardless of the amount of weight lost"—
Bill: Which is interesting because the lead researcher's actual quote was: "As it stands now, we do not know how to account for that other roughly two thirds of the benefit."
Alex: Hang on. "We do not know" somehow became "we discovered alternative mechanisms"?
Bill: That's exactly the gap we're looking at here.
Alex: Okay, but let's back up because millions of people are on these drugs. Why does this particular claim matter so much?
Bill: So these are GLP-1 receptor agonists—semaglutide is the generic name. Originally for diabetes, then they became massive for weight loss. And the SELECT trial showed they reduce major cardiovascular events by twenty percent. Heart attacks, strokes, cardiovascular death.
Alex: Which is genuinely significant.
Bill: Absolutely. But here's where it matters: if the drug only works through weight loss, then it's useful for people who are overweight or obese and manage to lose weight on it. But if it works through other mechanisms—direct effects on your heart, blood vessels, inflammation—
Alex: Then suddenly it's useful for way more patients.
Bill: Right. Even people who don't lose much weight, or who aren't particularly overweight to begin with. Which from a medical perspective is interesting, but from a commercial perspective—Novo Nordisk makes these drugs—it massively expands your potential market.
Alex: Right. So what did this study actually do? Because "two-thirds unexplained" sounds quite mysterious.
Bill: They did what's called a mediation analysis. You're trying to figure out: does A cause C directly, or does A cause B, which then causes C?
Alex: Give me a concrete example.
Bill: Okay, so let's say you find that people who drink coffee live longer. You'd want to know: is it the caffeine directly doing something? Is it that coffee drinkers sleep less and that somehow matters? Is it that they socialize more at coffee shops? Mediation analysis tries to measure those middle steps—the B in the chain from A to C.
Alex: Right, okay.
Bill: In this case, the question was whether semaglutide reduces heart attacks because it causes weight loss, which then reduces heart attacks.
Alex: Mmm.
Bill: So they measured weight loss—specifically waist circumference—and they found it explained about thirty-three percent of the cardiovascular benefit. Which left sixty-seven percent unexplained.
Alex: But unexplained doesn't mean "working through proven alternative mechanisms." It just means unexplained.
Bill: That's the whole issue. And here's what really matters: they only measured one thing as a potential explanation. Waist circumference.
Alex: Wait, sorry—what else did they measure in the trial? Because these big cardiovascular studies measure everything, don't they?
Bill: Oh yeah. Blood pressure, glucose levels, inflammatory markers like C-reactive protein, lipid profiles, insulin sensitivity—all the standard stuff.
Alex: So they had the data?
Bill: They had the data. They just didn't analyze those factors as potential mediators.
Alex: I'm sorry, what? They measured blood pressure changes, inflammation changes, all of that—things that absolutely affect your heart—and then they only checked whether waist circumference explained the benefits?
Bill: Correct. And when waist circumference only explained a third of it, they concluded two-thirds was unexplained.
Alex: But it's unexplained because they didn't bloody look at the other explanations they'd already measured!
Bill: Well, it's technically true that it's unexplained—
Alex: No, hang on. This is—from my journalism days, I recognize this pattern. It's not that the researchers are lying, but somewhere between the study and the headline, "we didn't measure this" became "we found something mysterious."
Bill: I mean, they did measure those things. They just didn't run the mediation analysis on them.
Alex: Right, which is the same problem, isn't it?
Bill: Actually, I think this might just be normal science. You can't analyze every possible mediator in one paper. Maybe they're planning follow-up analyses.
Alex: But that's not how it's being reported. The narrative is "miracle drug does even more than we thought through mysterious mechanisms," not "incomplete analysis reveals need for further research."
Bill: Okay, that's fair. The framing is definitely misleading.
Alex: Plus the commercial incentive. If you're Novo Nordisk—and they fully funded this study—proving your drug works through multiple mechanisms means more patients, more prescriptions, more revenue.
Bill: Which doesn't invalidate the science, but yeah, it's worth keeping in mind.
Alex: Wait, didn't we—I feel like we've talked about this exact thing before. With these same drugs?
Bill: The Ozempic face thing?
Alex: No, no. Something about... was it the Alzheimer's study?
Bill: Oh! Right, yeah. Where the headlines said GLP-1 drugs reduce Alzheimer's risk, but they hadn't actually controlled for the obvious confounders.
Alex: That was the same issue, wasn't it? They had measured all these things—weight loss, glucose control—
Bill: But didn't analyze them properly. Just looked at the association and ran with it.
Alex: Same drugs, same problem. Measured but not analyzed.
Bill: Although that one was observational data, this is an RCT. So it's not quite the same.
Alex: No, but the pattern is—anyway. What do we actually know about how these drugs work? Because I'm assuming they don't just magic away heart attacks.
Bill: We know quite a lot, actually. GLP-1 drugs reduce inflammation—C-reactive protein drops by twenty to sixty percent in studies. They lower blood pressure, partly independent of weight loss. They improve glucose control and insulin sensitivity. There's evidence they have direct effects on blood vessel lining and heart tissue.
Alex: So there probably are weight-independent mechanisms?
Bill: Almost certainly. The biology supports it. What this study doesn't do is prove which of those mechanisms explain the benefits they observed, because they didn't test for them.
Alex: Okay.
Bill: There's another thing that's interesting here. The cardiovascular benefits showed up really early—within twenty weeks—before patients had lost substantial weight.
Alex: Which does suggest something beyond just "you weigh less so your heart has less work to do."
Bill: Exactly. It could be those acute anti-inflammatory effects, blood pressure reduction, changes in fluid retention—things that happen quickly. But again, the study didn't analyze those as mediators.
Alex: This is what drives me spare about health headlines. The underlying reality—that these drugs work through multiple pathways, some related to weight loss and some not—is actually more interesting than either extreme. But it doesn't fit into a clean headline.
Bill: Right.
Alex: What about the patients in all this? Because if I'm someone with heart disease taking this drug, what am I supposed to do with these headlines?
Bill: That's the frustrating part. The practical answer doesn't change: if you have cardiovascular disease and obesity, these drugs reduce your risk of heart attacks and strokes by twenty percent. That's real and important.
Alex: Whether it's one hundred percent through weight loss or thirty-three percent through weight loss and sixty-seven percent through other pathways is almost a secondary question for patients.
Bill: Right. But here's why the misleading framing matters: if everyone thinks we've identified the mechanisms, future researchers might not look as hard for the actual answers.
Alex: Mmm.
Bill: And patients or doctors might make decisions based on false certainty.
Alex: Like assuming the drug will work even if you don't lose weight, when we don't actually have evidence for that specific scenario.
Bill: Or the opposite—thinking you've failed if you don't lose much weight, when maybe you're still getting cardiovascular benefits. We just don't know.
Alex: Okay, so I'm going to push back on something you said earlier. You said this might just be normal science—you can't analyze everything in one paper.
Bill: Yeah.
Alex: But this isn't "everything." Blood pressure and inflammation are the most obvious cardiovascular mechanisms. It's like—when I was covering health stories, if someone published a diet study and only measured weight but not cholesterol or blood sugar, that's not normal limitations. That's a choice.
Bill: Huh. That's actually a good point.
Alex: Right?
Bill: Yeah. When I was doing A/B testing, if we had the data and just... didn't look at it, that would be a problem. Especially if we then announced we'd found an unexplained effect.
Alex: Exactly. It's like saying "I measured the water content of this cake and it only explains thirty percent of why the cake tastes good," without ever measuring the sugar, butter, or eggs.
Bill: Okay, I'm convinced. This is more than normal limitations.
Alex: Thank you.
Bill: So what should people actually take away from this?
Alex: That even massive, well-designed studies published in top journals can be presented in misleading ways. The gap here isn't in the science itself—it's in the translation from "we measured one thing and it doesn't explain everything" to "we've discovered mysterious alternative mechanisms."
Bill: And the red flag to watch for is when uncertainty in the research gets turned into certainty in the headlines. The researchers were honest: they don't know what explains the other two-thirds. That should have been the headline.
Alex: Instead we got "benefits extend beyond weight loss," which implies we know what those other benefits are and how they work.
Bill: When really what we know is: we didn't look hard enough yet. Which is fine! That's how science works. You find something interesting, you design follow-up studies to investigate the mechanisms. You don't just declare the mystery solved.
Alex: And for anyone on these medications or considering them, the bottom line is they work for cardiovascular protection. The mechanism story is incomplete, but that doesn't change the clinical benefit.
Bill: Right.
Alex: Just maybe read past the headline before deciding what the science actually shows. Especially when there's a pharmaceutical company with billions in revenue depending on how that science gets interpreted.
Bill: And check whether the "unexplained" results are unexplained because they're mysterious, or unexplained because nobody measured the obvious things.
Alex: Which in this case—wait, did I say that right? They did measure them.
Bill: They measured them, but didn't analyze them as mediators.
Alex: Right. So it's not a mystery. It's a methodological choice that got reported as a scientific discovery.
Bill: That's... actually quite good. That's the whole story right there.
Alex: Thank you. I have my moments.